

In the Claims:

Please amend claims 21, 37, and 43 as follows, and cancel claims 4, 5, 39, 41 and 42, as follows:

1-20. (canceled)

21. (currently amended) A composition comprising the isolated polypeptide of ~~claim 4~~ claim 37 and a pharmaceutically-acceptable carrier.

22-36. (canceled)

37. (currently amended) An isolated mammalian REMODEL polypeptide, wherein the amino acid sequence of said REMODEL ~~polypeptide is selected from the group consisting~~ consists of ~~SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:5.~~

38. (withdrawn) The isolated mammalian REMODEL polypeptide of claim 37, wherein the amino acid sequence of said REMODEL polypeptide consists of SEQ ID NO:2.

39. (canceled)

40. (withdrawn) The isolated mammalian REMODEL polypeptide of claim 37, wherein the amino acid sequence of said REMODEL polypeptide consists of SEQ ID NO:5.

41-42. (canceled)

43. (currently amended) ~~The isolated chimeric polypeptide of claim 42~~ An isolated chimeric polypeptide comprising a tag polypeptide covalently linked to a mammalian REMODEL polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:4, wherein said tag polypeptide is selected from the group consisting of a green fluorescent protein tag polypeptide, an influenza virus hemagglutinin tag polypeptide, a myc tag polypeptide, a

glutathione-S-transferase tag polypeptide, a myc-pyruvate kinase tag polypeptide, a His6 tag polypeptide, a FLAG tag polypeptide, and a maltose binding protein tag polypeptide.

44. (Previously presented) A recombinant cell comprising the isolated polypeptide of claim 37.